Direct immunologic activities of CpG DNA and implications for gene therapy.
Vertebrate immune systems have evolved the ability to detect and be activated by most microbial and viral DNAs by virtue of their content of unmethylated 'CpG motifs', which are selectively suppressed in vertebrate DNA. Because their CpGs are also unmethylated, the DNA in gene therapy vectors routinely induces direct immune stimulation through activating this host defense mechanism. Administration of such 'CpG DNA' by injection or inhalation triggers rapid activation of B cells, monocytes, macrophages, dendritic cells, and natural killer cells, along with the release of pro-inflammatory cytokines. These immune stimulatory effects can be prevented by chloroquine and other drugs that interfere with endosomal maturation or by the presence of certain neutralizing DNA sequences, which block the immune stimulatory CpG motifs. Aside from serving as the genetic code, DNA can have direct immune activities. Vertebrate immune systems have evolved a defense mechanism that is able to broadly detect most microbial and viral DNAs because of differences in the frequency and methylation of CpG dinucleotides in particular base contexts. B cells, monocytes, macrophages, and dendritic cells spontaneously take up DNA of any type. If the DNA contains these immune stimulatory 'CpG-S motifs', the cells become activated within minutes and begin producing pro-inflammatory cytokines such as IL-6 and IL-12 and upregulate expression of co-stimulatory molecules. This results in the activation of both innate and acquired immune responses. The pro-inflammatory effects of CpG-S motifs are opposed by CpG dinucleotides in certain distinct base contexts, termed neutralizing or CpG-N motifs. Increasing the ratio of CpG-S to CpG-N motifs enhances the immune stimulatory effects of DNA, even if the total level of CpGs in the DNA is not altered. While this is useful in generating enhanced genetic vaccines, the opposite strategy is likely to become useful for the generation of gene therapy vectors with reduced inflammatory effects.
Krieg
A M
AM
Department of Veterans Affairs Medical Center, Iowa City, IA 52246, USA. arthur-krieg@uiowa.edu
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D001483:Base Sequence; D018899:CpG Islands / Q000235:genetics* / Q000276:immunology; D004247:DNA / Q000235:genetics* / Q000276:immunology / Q000494:pharmacology; D015316:Genetic Therapy / Q000009:adverse effects; D006801:Humans; D012449:Safety; D019444:Vaccines, DNA / Q000235:genetics / Q000494:pharmacology
D000276:Adjuvants, Immunologic; D019444:Vaccines, DNA; D004247:DNA